Involving Autoimmunity, Allergy, Immediate Hypersensitivity, Delayed Hypersensitivity, Immunosuppression, Or Immunotolerance Patents (Class 530/868)
  • Patent number: 8999339
    Abstract: The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status, with a therapeutically effective amount of an anti-IgE moiety. In accordance with the invention, COPD patients with an elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found to be useful for the treatment of COPD patients regardless of their skin test results and/or in vitro reactivity to a perennial aeroallergen. Anti-IgE moieties, in accordance with the invention, include but are not limited to any IgG antibody that selectively binds to a given mammal immunoglobulin E (e.g., human immunoglobulin E) such as humanized anti-IgE, humanized murine monoclonal antibody, and/or Omalizumab.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: April 7, 2015
    Inventor: Clifford G. Risk
  • Patent number: 8974794
    Abstract: The invention pertains to methods of using C?mX peptides (e.g., GLAGGSAQSQRAPDRVL; SEQ ID NO:2) that can bind effectively induce immune responses to membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: March 10, 2015
    Assignee: Academia Sinica
    Inventors: Tse Wen Chang, Jiun-Bo Chen, Pheidias C. Wu, Alfur F. Hung
  • Patent number: 8926973
    Abstract: Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: January 6, 2015
    Assignee: Merck Patent GmbH
    Inventors: Stephen D. Gillies, Jeffrey Way, Anita A. Hamilton
  • Patent number: 8828394
    Abstract: This invention relates to methods of treating IgE mediated disorders such as allergy and asthma based on activating surface-bound IgD molecules on basophils. The invention also relates to methods of making IgD, as well as methods of screening for antimicrobial agents from IgD-activated basophils.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: September 9, 2014
    Assignee: Cornell University
    Inventors: Andrea Cerutti, Kang Chen
  • Patent number: 8796426
    Abstract: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: August 5, 2014
    Assignee: Philogen S.p.A.
    Inventors: Dario Neri, Hans Dietrich Menssen, Andreas Menrad, Christoph Schliemann
  • Patent number: 8741294
    Abstract: The invention pertains to the generation and utility of antibodies that can bind effectively to C?mX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The C?mX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mIgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP (SEQ ID NO:1) peptide at the C-terminal of C?mX, have now been found to bind poorly to mIgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL (SEQ ID NO:2) and HSGQQQGLPRAAGGSVPHPR (SEQ ID NO:3), of C?mX can bind effectively to mIgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: June 3, 2014
    Assignee: Academia Sinica
    Inventors: Tsewen Chang, Jiun-Bo Chen, Pheidias C. Wu, Alfur F. Hung
  • Patent number: 8729247
    Abstract: A soluble multimeric protein or polypeptide is disclosed that is able to inhibit interaction of leukocyte Fc? receptors (Fc?R) and immunoglobulin G (IgG). The protein or polypeptide comprises two or more linked Fc binding regions, at least one of which is derived from an Fc?R type receptor and, particularly, Fc?RIIa. Also described are polynucleotide molecules encoding the protein or polypeptide and the use thereof in methods of treating a subject for an immune-complex (IC)-mediated inflammatory disease.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: May 20, 2014
    Assignee: Trillium Therapeutics, Inc.
    Inventors: Phillip Mark Hogarth, Bruce David Wines
  • Patent number: 8722053
    Abstract: The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier, compositions comprising the immunogens, and methods for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: May 13, 2014
    Assignee: Pfizer Vaccines LLC
    Inventors: Brian Robert Champion, David Robert Stead, Paul Andrew Wright
  • Patent number: 8679503
    Abstract: The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: March 25, 2014
    Assignee: Yale University
    Inventors: Jack A. Elias, Zhou Zhu
  • Patent number: 8642041
    Abstract: The present invention relates to the use of Adenylyl Cyclase-Associated Protein (CAP1) as a target for immuno-modulation. More specifically, the invention relates to the use of compounds that interact and bind CAP1, specifically, anti-CAP1 antibodies, and/or to CAP1 molecule or any fragments thereof, for the treatment of immune-related disorders by modulation of the Th1/Th2 balance. The invention further provides screening method for immuno-modulatory compounds that interact with CAP1.
    Type: Grant
    Filed: March 21, 2010
    Date of Patent: February 4, 2014
    Assignee: Protab Ltd.
    Inventors: Yaakov Naparstek, Eli Moallem
  • Patent number: 8632775
    Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: January 21, 2014
    Assignee: Genentech, Inc.
    Inventors: Lawren Wu, Mercedesz Balazs, Hans Brightbill, Andrew Chan, Yvonne Chen, Anan Chuntharapai, Mark Dennis, Terence Wong
  • Patent number: 8598312
    Abstract: The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: December 3, 2013
    Assignee: Provid Pharmaceuticals, Inc.
    Inventors: Gary Lee Olson, Charles Michael Cook, Christopher Raymond Self
  • Patent number: 8580269
    Abstract: Compositions and methods for stimulating an immune response against cells that express survivin are provided. The method is suitable for prophylaxis and/or therapy of autoimmune disorders. The method involves administering to an individual a composition that contains a survivin peptide mimic that has a cysteine to methionine alteration at amino acid position 57 of wild type survivin. Fragments of the peptides can also be used.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: November 12, 2013
    Assignee: Health Research, Inc.
    Inventors: Michael J. Ciesielski, Robert A. Fenstermaker
  • Patent number: 8545843
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: October 1, 2013
    Assignees: Genentech, Inc., Biogen Idec Inc.
    Inventors: John G. Curd, Antonio J. Grillo-Lopez
  • Patent number: 8475801
    Abstract: The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.
    Type: Grant
    Filed: August 1, 2012
    Date of Patent: July 2, 2013
    Assignee: Pfizer Vaccines, LCC
    Inventors: Alan Daniel Brown, Brian Robert Champion, Clare Christy, David Paul Gervais, Lyn Howard Jones, Anne Maria Kristina Kjerrstrom, David Cameron Pryde, Lee Richard Roberts, David Michael Wyatt
  • Patent number: 8460664
    Abstract: The invention pertains to the generation and utility of antibodies that can bind effectively to C?mX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The C?mX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mIgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP (SEQ ID NO:1) peptide at the C-terminal of C?mX, have now been found to bind poorly to mIgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL (SEQ ID NO:2) and HSGQQQGLPRAAGGSVPHPR (SEQ ID NO:3), of C?mX can bind effectively to mIgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE.
    Type: Grant
    Filed: February 25, 2010
    Date of Patent: June 11, 2013
    Assignee: Academia Sinica
    Inventors: Tsewen Chang, Jiun-bo Chen, Pheidias C Wu, Alfur F Hung
  • Patent number: 8404236
    Abstract: The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored immunoglobulins and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to deplete those B cells and plasma cells expressing the novel epitopes of the invention. The antibodies of the present invention can be useful for the treatment of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells. Accordingly the present invention also provides compositions and methods for the prevention, management, treatment or amelioration of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: March 26, 2013
    Assignee: MedImmune, LLC
    Inventors: Herren Wu, Peter Kiener, Partha S. Chowdhury, James F. Young
  • Patent number: 8372400
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: February 12, 2013
    Assignee: Abbott Biotechnology Ltd.
    Inventors: Jochen G. Salfeld, Deborah J. Allen, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, Hendricus R. J. M. Hoogenboom, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
  • Patent number: 8354109
    Abstract: A soluble multimeric protein or polypeptide is disclosed that is able to inhibit interaction of leukocyte Fc? receptors (Fc?R) and immunoglobulin G (IgG). The protein or polypeptide comprises two or more linked Fc binding regions, at least one of which is derived from an Fc?R type receptor and, particularly, Fc?RIIa. Also described are polynucleotide molecules encoding the protein or polypeptide and the use thereof in methods of treating a subject for an immune-complex (IC)-mediated inflammatory disease.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: January 15, 2013
    Assignee: Suppremol GmbH
    Inventors: Phillip Mark Hogarth, Bruce David Wines
  • Patent number: 8337844
    Abstract: A method of treating an autoimmune disease comprising administering to a patient a therapeutically effective amount of a CD20-binding polypeptide composition comprising a combination of a modified heavy chain variable region polypeptide and a modified light chain variable region polypeptide. The combination can be (a) a modified 2B8 antibody heavy chain variable region polypeptide of SEQ ID NO: 48; and a modified 2B8 antibody light chain variable region polypeptide of SEQ ID NO: 49; or (b) a modified Leu16 antibody heavy chain variable region polypeptide of SEQ ID NO: 50; and a modified Leu16 antibody light chain variable region polypeptide of SEQ ID NO: 51.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: December 25, 2012
    Assignee: Merck Patent GmbH
    Inventors: Francis Joseph Carr, Stephen Williams, Stephen D. Gillies
  • Patent number: 8334146
    Abstract: The binding specificity of at least one plasma protein suspended or dissolved in a liquid medium is altered by exposing the protein to an oxidizing agent or an electric current sufficient to alter its binding specificity. A masked protein such as an autoantibody can be recovered from blood or blood products or extracts by oxidizing the protein to change its binding specificity.
    Type: Grant
    Filed: April 23, 2008
    Date of Patent: December 18, 2012
    Assignee: Redox-Reactive Reagents LLC
    Inventor: John A. McIntyre
  • Patent number: 8222211
    Abstract: A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a TH2 type cytokine bias. In addition PIF peptides enhance endometrial receptivity by increasing adhesion molecules expression. PIF biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages. PIF peptides, which are immune modulators, therefore may have diagnostic and non toxic therapeutic applications in improving fertility, reducing pregnancy loss as well may be useful when administered for the treatment of autoimmune diseases and for prevention xenotransplants rejection.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: July 17, 2012
    Assignee: BioIncept, LLC
    Inventor: Eytan R. Barnea
  • Patent number: 8178098
    Abstract: Disclosed is a method to reduce airway hyperresponsivesness in an animal by the direct delivery to the lungs of aerosolized antibodies against T cell receptors. The method is particularly useful for treating airway hyperresponsiveness associated with allergic inflammation, is effective at extremely low doses of antibody, and does not have a substantial effect on the peripheral immune system.
    Type: Grant
    Filed: April 3, 2001
    Date of Patent: May 15, 2012
    Assignee: National Jewish Health
    Inventors: Michael F. Lahn, Willi K. Born, Arihiko Kanehiro, Erwin Gelfand
  • Patent number: 8137670
    Abstract: The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored IgE and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to deplete those B cells and plasma cells expressing the novel epitopes of the invention. The antibodies of the present invention can be useful for the treatment of IgE-mediated diseases. Accordingly the present invention also provides compositions and methods for the prevention, management, treatment or amelioration of IgE-mediated diseases.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: March 20, 2012
    Assignee: MedImmune, LLC
    Inventors: Herren Wu, Peter Kiener, Partha S. Chowdhury, James F. Young
  • Patent number: 8030007
    Abstract: A method for diagnosing endometriosis in a human subject comprising the steps of detecting a test amount of an antibody that specifically binds to SEQ ID NO: 6 polypeptide or a truncated peptide comprising an epitope of SEQ ID NO: 6 in a sample from the subject; and comparing the test amount with a normal range of the antibody in a control sample from a subject who does not suffer from endometriosis, whereby a test amount above the normal range provides a positive indication in the diagnosis of endometriosis.
    Type: Grant
    Filed: March 3, 2011
    Date of Patent: October 4, 2011
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: A. Said El Shami, Bruce Campbell, Dennis Sustarsic, Niver Sahakian
  • Patent number: 7943334
    Abstract: The present invention provides an immunological detection method that can detect milk allergens, allergens of albumen, flour, buckwheat and peanut with high sensitivity in foods containing these allergens regardless they are denatured/native, and a detection kit to be used therefor. It is a method for detecting allergens by using 2 or more monoclonal antibodies recognizing native and denatured milk allergens, native and denatured albumen allergens, native and denatured flour allergens, native and denatured buckwheat allergens, and native and denatured peanut allergens, using asl casein which is the main protein of milk casein, ?-lactoglobulin which is the main protein of whey, ovalubumin and ovomucoid which are main proteins of albumen, gliadin which is the main protein of flour, protein with a molecular weight of 24 kDa and 76 kDa which are main proteins of buckwheat, and Ara h1 which is the main protein of peanut as an index.
    Type: Grant
    Filed: March 4, 2005
    Date of Patent: May 17, 2011
    Assignee: Prima Meat Packers, Ltd.
    Inventors: Masanobu Akimoto, Shigeki Katou, Makoto Namioka
  • Patent number: 7897151
    Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides derived from the CH3 domain or junction of Ch-3/CH4 domain of an IgE molecule and methods for the evaluation of IgE mediated allergies in dogs.
    Type: Grant
    Filed: August 4, 2005
    Date of Patent: March 1, 2011
    Assignee: Pharmacia & Upjohn Company, LLC
    Inventors: Mohamad A. Morsey, Michael G. Sheppard, David W. Wheeler
  • Patent number: 7811570
    Abstract: Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody/fragment which specifically binds to targeted organ, tissue or cell. The antibody/fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent.
    Type: Grant
    Filed: September 20, 2005
    Date of Patent: October 12, 2010
    Assignee: Immunomedics, Inc.
    Inventor: David M. Goldenberg
  • Patent number: 7772368
    Abstract: The present invention relates to IgE-dependent histamine releasing factor (HRF) and HRF-binding peptides, more precisely, deletion forms of HRF which are able to be formed as dimers containing amino acid sequence represented by SEQ ID NO:3, genes encoding thereof and novel HRF-binding peptides having an activity of inhibiting HRF. The deletion forms of HRF which are able to be formed as dimers of the present invention induces intracellular secretion of histamine and IL-8, making an excellent candidate for a drug for inhibiting allergic reaction triggered by HRF and a kit for detecting HRF in serum of an allergy patient. In addition, novel HFR-binding peptides of the present invention bind to HRF to inhibit the actions of HFR, so they can be effectively used for the prevention and the treatment of allergic diseases of animals including asthma and rhinitis or malaria.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: August 10, 2010
    Assignee: Ewha University-Industry Collaboration Foundation
    Inventors: Kyunglim Lee, Miyoung Kim
  • Patent number: 7767791
    Abstract: The invention involves assays, diagnostics, kits, and assay components for determining levels of K41-glycated CD59 in subjects. Treatments for subjects based upon levels of K41-glycated CD59 also are provided.
    Type: Grant
    Filed: April 27, 2006
    Date of Patent: August 3, 2010
    Assignee: President and Fellows of Harvard College
    Inventor: Jose Halperin
  • Patent number: 7588763
    Abstract: This application relates to methods for modulating an immune response in a mammalian subject in need of prevention against or treatment of diabetes comprising the administration of EtxB and/or insulin.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: September 15, 2009
    Assignee: Trident Pharmaceuticals, Inc.
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, Toufic Osman Nashar
  • Patent number: 7588761
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: September 15, 2009
    Assignee: Abbott Biotechnology Ltd.
    Inventors: Jochen G. Salfeld, Deborah J. Allen, Hendricus R. J. M. Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
  • Patent number: 7582735
    Abstract: The invention relates to: nucleic acid molecules encoding the light chain and heavy chain of feline immunoglobulin E (IgE), including species-specific regions of feline IgE; proteins encoded by the nucleic acid molecules; inhibitors to the nucleic acids and proteins; antibodies to the proteins; cells transformed with the nucleic acid molecules; assays employing the transformed cells, nucleic acids, antibodies and/or proteins or portions thereof; methods for treating IgE-mediated responses (ie. allergy) using the materials provided; methods for eliciting an immune response to IgE and kits containing the nucleic acid molecules, proteins or derivatives thereof (ie. antibodies).
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: September 1, 2009
    Assignee: Heska Corporation
    Inventors: Catherine McCall, Eric Weber
  • Patent number: 7544783
    Abstract: This invention provides a fusion protein (FP4) and the code gene, expression method, and clinical application; its goal is to provide a fusion protein, the code gene, and the expression method as well as to take this fusion protein as the active constituent anti-allergic medicine. In addition, the invention provides the sequence of fusion protein attached on SEQ ID 2 and any derivation protein of the fusion protein (FP4) which includes adding or deleting several amino acids of SEQ ID 2 as well as increasing or deducing nuclear tides of SEQ ID 1. We designed to cross-link IgE active receptor and an IgG inhibitory receptor by endogens hinge without any extraneous chemical link. This invention fusion protein has function to block the IgE acceptor, moreover fragment of fusion protein has ability to specifically bind to a native IgG inhibitory receptor containing immunoreceptor tyrosine-based inhibitory motif, thereby inhibiting the IgE-driven mediator release from mast cells and basophils.
    Type: Grant
    Filed: May 8, 2004
    Date of Patent: June 9, 2009
    Assignees: Xianggui Wu, Jun Bao
    Inventors: Haiming Chen, Junyu Gao
  • Patent number: 7488804
    Abstract: The present invention comprises a fusion molecule comprising a Fc? fragment sequence including functionally active CH2, CH3 and CH4 domains of the constant region of an IgE heavy chain (CH?2-CH?3-CH?4 sequence) linked at its C-terminus to the N-terminus of a second polypeptide including functionally active hinge, CH2 and CH3 domains of the constant region of an IgG1 heavy chain (?hinge-CH?2-CH?3 sequence), pharmaceutical compositions comprising the fusion molecule and methods of treatment using the fusion molecule.
    Type: Grant
    Filed: February 2, 2005
    Date of Patent: February 10, 2009
    Assignee: The Regents of the University of California
    Inventors: Andrew Saxon, Ke Zhang, Daocheng Zhu
  • Patent number: 7485708
    Abstract: It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by masking the site with a compound that prevents IgE binding or by altering as little as a single amino acid within the protein, most typically a hydrophobic residue towards the center of the IgE binding epitope, to eliminate IgE binding. The method allows the protein to be altered as minimally as possible, other than within the IgE-binding sites, while retaining the ability of the protein to activate T cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity. The examples use peanut allergens to demonstrate alteration of IgE binding sites. The critical amino acids within each of the IgE binding epitopes of the peanut protein that are important to immunoglobulin binding have been determined.
    Type: Grant
    Filed: August 26, 2002
    Date of Patent: February 3, 2009
    Assignee: University of Arkansas
    Inventors: A. Wesley Burks, Jr., Gary A. Bannon, Hugh A. Sampson, Ricki M. Helm, J. Steven Stanley, Patrick A. Rabjohn
  • Patent number: 7482010
    Abstract: The invention relates to a hypoallergenic immunogenic molecule derived from the Phl p 6 allergen, wherein the Phl p 6 molecule has an N-terminal and/or C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity. The invention also relates to a hypoallergenic immunogenic combination of molecules derived from the Phl p 6 allergen, comprising (i) a Phl p 6 molecule having an N-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, and (ii) a Phl p 6 molecule having a C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, which two molecules together encompass the complete sequence of Phl p 6. The invention further relates to the use of the hypoallergenic immunogenic molecule or molecule mixture in hyposensitization and diagnosis.
    Type: Grant
    Filed: November 27, 2002
    Date of Patent: January 27, 2009
    Assignee: Phadia AB
    Inventors: Rudolf Valenta, Susanne Vrtala, Sabine Stummfoll, Hans Grönlund, Monika Grote, Luca Vangelista, Annalisa Pastore, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft
  • Patent number: 7479540
    Abstract: Adipomodulin (a light chain molecule) and related molecules and methods useful in the treatment of obesity and obesity-related disorders.
    Type: Grant
    Filed: April 5, 2005
    Date of Patent: January 20, 2009
    Inventors: Chandan Prasad, Julio E. Figueroa, II, Parakat Vijayagopal
  • Patent number: 7425339
    Abstract: The present invention provides modified CD8 molecules whose binding to MHC is enhanced compared to wild-type CD8, wherein Ser53 of at least one CD8? chain thereof is mutated to another amino acid. It also provides nucleic acids encoding such molecules and methods of using such molecules and nucleic acids in immunosuppressive therapy, in particular as inhibitors of cytotoxic T cell responses.
    Type: Grant
    Filed: June 14, 2002
    Date of Patent: September 16, 2008
    Assignee: MediGene Limited
    Inventors: Bent Karsten Jakobsen, Meir Glick
  • Patent number: 7399471
    Abstract: Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the FIGS. 1a to 16b. The obtained polypeptides, being Fab fragments, MAY be used directly as an active ingredient in pharmaceutical and diagnostic compositions. The Fab and their DNA sequences can also be used for the preparation of complete recombinant Anti-Rhesus D antibodies. Useful in pharmaceutical and diagnostic compositions.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: July 15, 2008
    Assignee: ZLB Behring AG
    Inventors: Andreas Morell, Martin Imboden, Beda Stadler, Sylvia Miescher, Monique Vogel, Hanspeter Amstutz
  • Patent number: 7393529
    Abstract: The invention provides methods and compositions for inhibiting binding of IgE to a high affinity receptor. The methods and compositions are useful in the treatment of allergic diseases and allergy symptoms in mammals.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: July 1, 2008
    Assignee: IDEXX Laboratories, Inc.
    Inventors: Eugene Regis Krah, III, Robert Lawton
  • Patent number: 7368542
    Abstract: The binding specificity of at least one plasma protein suspended or dissolved in a liquid medium is altered by exposing the protein to an oxidizing agent or an electric current sufficient to alter its binding specificity. A masked protein such as an autoantibody can be recovered from blood or blood products or extracts by oxidizing the protein to change its binding specificity.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: May 6, 2008
    Assignee: Redox-Reactive Reagents LLC
    Inventor: John A. McIntyre
  • Patent number: 7326769
    Abstract: The invention relates to a method for quickly and effectively isolating and purifying five, namely the group 1, 2, 3, 10 and 13 allergens from grass pollen. The purification of said grass pollen is based on the inventive combination of hydrophobic interaction chromatography, gel filtration and cation exchange chromatography. The proteins obtained by the inventive method facilitate an improved diagnosis of pollen allergies and are used in pharmaceutical preparations for the therapy of pollenogenic diseases.
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: February 5, 2008
    Assignee: Merck Patentgesellschaft Mit Beschrankter Haftung
    Inventors: Roland Suck, Oliver Cromwell, Helmut Fiebig
  • Patent number: 7320873
    Abstract: The invention describes a method to diagnose the autoimmune disease activity by detecting the presence of an autoimmune specific MHC-peptide complex in a patient suffering from an autoimmune disease. The MHC-peptide complex is associated with rheumatoid arthritis. Monoclonals antibodies to be used for this method are also described. The antibodies can also be used for therapeutic purposes.
    Type: Grant
    Filed: August 8, 2001
    Date of Patent: January 22, 2008
    Assignee: N.V. Organon
    Inventor: Petrus Gerardus Antonius Steenbakkers
  • Patent number: 7279158
    Abstract: The use of compounds that block complement component C5 or its active fragments C5a and/or C5b (such compounds collectively referred to as “C5 blockers”) to treat established joint inflammation (arthritis) is disclosed. Administration of such C5 blockers has been found to: 1) arrest and/or reduce inflammation in joints which are already inflamed, and 2) inhibit the spread of inflammation to unaffected joints.
    Type: Grant
    Filed: January 5, 2005
    Date of Patent: October 9, 2007
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Yi Wang, Louis Matis
  • Patent number: 7252826
    Abstract: The present invention provides a modified Dermatophagoides pteronyssinus allergen Der p 5 protein which has ability to inhibit IgE binding when exposed against to the antigen. A method for treating allergy comprising administrating a therapeutically effective dose of the modified D. pteronyssinus allergen Der p 5 protein to a subject suffering from allergy Der p 5 is also provided.
    Type: Grant
    Filed: September 4, 2003
    Date of Patent: August 7, 2007
    Assignee: GenMont Biotech Inc.
    Inventors: Ching-Hsiang Hsu, Wei-Chih Su
  • Patent number: 7244431
    Abstract: The present invention relates to a pharmaceutical composition containing a peptide and a pharmaceutically acceptable carrier or diluent wherein the peptide has a length of 8 to 50 amino acids, at least three preferably consecutive amino acids of the peptide are identical to at least three amino acids which appear in close vicinity on the molecular surface of an allergenic protein, and said at least three amino acids are solvent-exposed amino acids in the allergenic protein. The invention also concerns a method for the preparation of the pharmaceutical composition.
    Type: Grant
    Filed: December 27, 2001
    Date of Patent: July 17, 2007
    Inventors: Margarete Focke, Vera Mahler, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft, Rudolf Valenta
  • Patent number: 7226996
    Abstract: The present invention relates to equine Fc epsilon receptor alpha chain nucleic acid molecules, proteins encoded by such nucleic acid molecules, antibodies raised against such proteins, and inhibitors of such proteins. The present invention also includes methods to detect IgE using such proteins and antibodies. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to mediate Fc epsilon receptor-mediated biological responses.
    Type: Grant
    Filed: March 21, 2005
    Date of Patent: June 5, 2007
    Assignee: Heska Corporation
    Inventors: Eric R. Weber, Catherine A. McCall
  • Patent number: 7211408
    Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.
    Type: Grant
    Filed: June 16, 2003
    Date of Patent: May 1, 2007
    Assignee: Merck Patent GmbH
    Inventors: Bruce L. Rogers, Jay P. Morgenstern, Julian F. Bond, Richard D. Garman, Julia L. Greenstein, Mei-Chang Kuo, Malcolm Morville
  • Patent number: 7204981
    Abstract: Method of treating a disease or pathological condition with activated protein C or a compound having activated protein C activity by direct regulation of the expression of specific genes associated with the disease or pathological condition.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: April 17, 2007
    Assignee: Eli Lilly and Company
    Inventors: Angelina Vucic Ciaccia, Lawrence Mark Gelbert, Brian William Grinnell, Bryan Edward Jones, David Eugene Joyce